Over the past twenty years, lung cancer research and care have entered a new era. One filled with hope, innovation, and progress that is transforming what it means to face a lung cancer diagnosis. From groundbreaking early detection efforts to life-extending treatments, each step forward represents years of collaboration between researchers, patients, and others in the lung cancer community.
Today, LUNGevity celebrates five exciting areas of progress that highlight the incredible strides made through sustained lung cancer research.
1. The Precancer Genome Atlas: Stopping Lung Cancer Before It Starts
The Precancer Genome Atlas helps scientists understand how healthy lung cells turn into cancerous ones. By mapping these early molecular changes, researchers can figure out how to stop lung cancer while it is still in the precancerous stage. This foundational work may one day pave the way for true prevention, where precancerous lesions are routinely detected and stopped before they develop into full-blown cancer.
2. Lung Cancer Screening: Detecting Early, Saving Lives
Low-dose CT screening has revolutionized early detection, finding lung cancers at stages when they are most treatable. Screening is now a proven tool that can reduce deaths from lung cancer. Continued efforts to expand access and awareness of lung cancer screening have enabled more people to benefit from this life-saving technology.
3. Biomarker Testing: A Game Changer for Precision Medicine
Biomarker testing has redefined how lung cancer is treated. By identifying specific mutations and alterations that drive tumor growth, doctors can now match patients to therapies tailored to their cancer’s biology. This shift toward precision medicine has given rise to targeted treatments. Precision medicine is also allowing more effective use of immune-based treatments to extend survival and improve quality of life.
4. New Treatment Options
With the dedicated efforts of advocates, patients, and researchers, the treatment landscape for lung cancer continues to expand. In 2025, six new treatment approaches were approved by the US Food and Drug Administration (FDA) to treat non-small cell lung cancer (NSCLC) or small cell lung cancer (SCLC):
- First Maintenance Treatment for Extensive-Stage SCLC
- First Oral Targeted Therapy for Advanced HER2+ NSCLC
- New Treatment for Patients with Metastatic NSCLC with EGFR Exon 20 Insertion Mutations
- New Treatment Approved for NSCLC with ROS1 Rearrangements
- New ADC Treatment Approved for Advanced EGFR+ NSCLC
- New Treatment Approved for NSCLC with High Level of c-MET Protein
These advances remind us that more personalized and effective options for patients are on the horizon.
5. Survivorship: Redefining What It Means to Live with Lung Cancer
Today, more people are living longer with lung cancer. Survivorship has become part of the lung cancer vocabulary. Survivorship programs focus on long-term care, mental health, and quality of life, ensuring that every survivor’s journey is supported. This growing community of survivors is a testament to how science and advocacy have come together to transform what it means to be diagnosed with lung cancer.
From early detection to survivorship, these advancements reflect a powerful truth: science saves lives. With continued support for research and advocacy, the future of lung cancer care is brighter than ever.
Get research news sent directly to your inbox by signing up for the quarterly LUNGevity Research Newsletter.